💀 Health Care Legal/Regulatory 🇺🇸 USA

23andMe

Democratized genetic testing through $99 mail-in kits, turning ancestry and health insights into a viral consumer product during the genomics cost revolution.

Lifespan
2006 — 2025
19 years
Total funding
$1.1B
Product type
Medical

💀 Cause at a glance

Primary cause
Data acquisition and processing costs ran too high
Decline chain
Data sources get harder → processing and compliance costs climb → freshness or coverage drops → paid value collapses
Key constraint
Stability, compliance, and freshness of data sources cap the product
Agent re-assessment
Agents can partially relieve the main cause, but human oversight remains
Lesson
Do not anchor product value on data sources you cannot control
Context
23andMe (Health Care · Medical, operated 19 years, total funding $1100M)

🤖 Agent -era re-read

Partially dissolved
Original cause category
数据获取与处理
Restart barrier
低代码可启动
Suggested agent architecture
Data processing agent · Automated workflow
Opportunity verdict

数据获取与整理是主要成本，Agent 能降低处理成本，但数据源合规与时效性仍需人工把控。

Residual risks (not solved by agents)
Trust and compliance risk Acquisition cost still high Quality stability

Rating: how well the original cause is dissolved in the Agent era；Auto-tagged by rules, pending human review

🔒 完整失败复盘 · Members only

Actionable lessons (The Loot)、Market analysis、五要素重建计划与创始人/投资人信息为 VIP Content， 解锁后查看完整避坑清单与重开方案。

🔥 Actionable lessons (The Loot)
📊 Market analysis
🔄 五要素重建计划
👤 创始人与投资人
升级 VIP 解锁完整复盘